Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New drugs for dermatologic diseases.

R K Landow1

  • 1University of Southern California School of Medicine, Los Angeles.

Dermatologic Clinics
|October 1, 1988
PubMed
Summary

Cyclosporine, a key immunosuppressant, has proven effective for psoriasis treatment. Monitoring blood levels is crucial due to drug interactions and narrow safety windows for optimal therapeutic outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The interferons. A clinician's view.

Dermatologic clinics·1988
Same author

Etretinate. A clinician's view.

Dermatologic clinics·1988
Same author

Differential diagnosis and treatment of pigmented skin lesions.

Comprehensive therapy·1988
Same author

Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis.

Journal of the American Academy of Dermatology·1988
Same author

Dermatology-important advances in clinical medicine: diagnosis of primary melanoma.

The Western journal of medicine·1983
Same author

Dermatology-important advances in clinical medicine: surgical treatment of primary malignant melanoma.

The Western journal of medicine·1983

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Cyclosporine, isolated less than 20 years ago, is a vital immunosuppressant in transplantation.
  • A 1979 observation suggested cyclosporine's potential therapeutic benefits for psoriasis patients.
  • Subsequent clinical trials have validated its efficacy in treating psoriasis, with decreasing dosages over time.

Purpose of the Study:

  • To review the established and emerging applications of cyclosporine in dermatological conditions.
  • To highlight the importance of therapeutic drug monitoring for cyclosporine in psoriasis management.
  • To discuss the pharmacokinetic considerations and drug interactions associated with oral cyclosporine therapy.

Main Methods:

  • Review of clinical trials and pharmacological data concerning cyclosporine in psoriasis.
  • Analysis of pharmacokinetic properties, including drug sequestration and absorption variability.
  • Examination of T-lymphocyte function as the primary mechanism of action.

Main Results:

  • Cyclosporine demonstrates significant efficacy in treating psoriasis, with optimal results achieved at reduced dosages.
  • Oral administration requires careful adherence due to drug adherence issues and potential for variable absorption.
  • Therapeutic drug monitoring is essential to maintain cyclosporine concentrations within a narrow safety and efficacy window.
  • Interactions with other medications (e.g., erythromycin, prednisone, ketoconazole) can significantly alter cyclosporine blood levels.

Conclusions:

  • Cyclosporine is a valuable therapeutic agent for psoriasis, requiring meticulous monitoring for safe and effective use.
  • Understanding cyclosporine's mechanism of action, primarily through T-lymphocyte inhibition, is key to its application.
  • Alternative treatments like clofazimine may be considered for refractory cases, such as palmoplantar pustulosis.

Related Experiment Videos